US 11873491
Complement component C5 iRNA compositions and methods of use thereof
granted A61KA61K31/713A61K39/3955
Quick answer
US patent 11873491 (Complement component C5 iRNA compositions and methods of use thereof) held by Alnylam Pharmaceuticals, Inc. expires Mon Jan 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Alnylam Pharmaceuticals, Inc.
- Grant date
- Tue Jan 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jan 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 32
- CPC classes
- A61K, A61K31/713, A61K39/3955, A61P, A61P1/04